Roche Pharmaceutical Development and Sales Overview

YTD Sep 2022: Portfolio diversification accelerating Ocrevus 17% Hemlibra 28% Evrysdi Phesgo Vabysmo Tecentriq Alecensa 101% 150% n/a 10% 16% Kadcyla 11% Perjeta Xolair Polivy Enspryng Gazyva Tamiflu Gavreto Esbriet Lucentis Herceptin 5% 10% 79% 108% 8% 56% 299% -25% US -25% -18% Europe Ronapreve -36% MabThera -20% Actemra/RoActemra -23% Japan International Avastin -29% -800 -400 0 400 Absolute values and growth rates at Constant Exchange Rates (CER) 800 Roche 18

View entire presentation